

---

Subject	Evaluation Advisory Committee Chair Report
---------	--

---

Category	For Information
----------	-----------------

---

### **Section A: Introduction**

- This report provides the Board with an overview of the activities of, and guidance provided by, the Evaluation Advisory Committee (EAC) since the Committee Chair last reported to the Board in December 2023.
- At the in-person EAC meeting on 20-21 March 2024, the EAC provided guidance on: (i) progress of the commissioned Gavi 5.1 centralised evaluations including the proposed centralised evaluation on sustainability/post transition; (ii) the Zero-Dose Evaluation; (iii) the Mid-Term Evaluation (MTE) of Gavi's 2021-2025 Strategy; (iv) the COVAX Evaluation; (v) centralised evaluation work planning for Gavi 6.0; (vi) the Evaluation Function Review planned for 2024; and (vii) EAC engagement in Gavi 5.1 evaluations.

### **Section B: Overarching issues and guidance**

- The EAC continued to consider its remit, voice and practice in supporting a Gavi evaluation portfolio of optimal independence, credibility and utility. The ongoing MOPAN assessment and the forthcoming Evaluation Function Review will offer useful inputs into this process.
- The EAC provided guidance on the development of the Gavi 6.0 Centralised Evaluation Workplan (CEWP). Regarding stakeholder consultation, the EAC encouraged the Secretariat to: (i) consult stakeholders and relevant partners; and (ii) map against other evidence generation functions such as Learning Hubs, audits, decentralised evaluations. On the proposed principles for the Gavi 6.0 CEWP, the EAC advised to: (i) clarify the purpose of the proposed principles for work planning; (ii) revisit content ahead of September 2024 meeting to align with policy aims of credibility, utility and independence; and (iii) include issues of country representation/evidence partnerships. The EAC provided feedback on potential topics for discussion at the September 2024 meeting related to principles, approaches, methods and data issues with implications for evaluation work planning for Gavi 6.0.
- Regarding the Evaluation Function Review, the EAC advised for arrangements to be put in place to ensure independence and oversight of the review, including: bringing in key stakeholders across Gavi's Board, Programme and Policy Committee (PPC) and Senior Leadership Team, and keeping them informed early and throughout the process. EAC members also noted that this review should consider the implications of all relevant development trends (e.g. Leave No One Behind, localisation, subnational focus, Lusaka Agenda, and partnership) and advised that a survey be added to the methodology for the

review. Moreover, the EAC was updated on the MOPAN assessment process and timelines.

### **Section C: Specific guidance on the centralised evaluation portfolio**

- When discussing progress on the Gavi 5.1 centralised evaluation workplan, the EAC supported the Secretariat's proposal to postpone the sustainability/post-transition evaluation to 2025, and to revisit the topic at the September 2024 EAC meeting. The EAC: (i) requested an update and additional information about the MICs approach learning agenda to inform the focus and value add of evaluative work on sustainability/MICs; and (ii) raised the importance as well of differentiating between former-Gavi-eligible countries and the never-Gavi-eligible countries. Furthermore, EAC members encouraged the Secretariat to continue the collaborative endeavour to expand the evaluation supplier pool, working in partnership with other Global Health Institutions. In terms of potential forthcoming evaluations, the EAC will discuss the African Vaccine Manufacturing Accelerator (AVMA) evaluation plan and a Big Catch-Up evaluation in September 2024.
- Concerning the Zero-Dose Evaluation, the EAC supported the plans for Phase 2. EAC members advised that evaluators should use all available relevant decentralised evaluation reports/information from Learning Hubs and reflect this in their reports; and emphasised the importance of in-depth country case study data and exploration of data sources for availability of data for contribution analysis, including communication with the partners like UNICEF, World Bank and WHO, resulting in an analysis plan.
- With respect to the Mid-Term Evaluation, the EAC requested feedback at the next EAC meeting on the perceived usefulness of the evaluation, including both in relation to what new insights were generated that inform course correction and the Gavi 6.0 strategy. Additionally, recognising the importance of clear concepts for evaluations, the EAC Focal Points will prepare definitions / notes on relevant topics such as what is expected in terms of "country voice," to inform future RFP development, and to be discussed at the next EAC meeting.
- On the COVAX Evaluation Phase 2, the EAC advised that a plan be developed to extract maximum learning from a joint evaluation, and emphasised the importance of examining partnership and how the Alliance is working; with a particular focus on coordination and implementation at country level. EAC members also advised the development of a strategy for providing findings back to case study countries.
- The EAC Chair report is attached in the form of a presentation as Annex A and the EAC meeting guidance and decisions are attached as Annex B and C.
- Gavi's Annual Evaluation Report for 2023 has been made available as Appendix 1.

## **Annexes**

**Annex A:** EAC Chair Report

**Annex B:** EAC Meeting Guidance, 20-21 March 2024

**Annex C:** EAC Review of Decisions, 20-21 March 2024

**Additional information available on BoardEffect**

**Appendix 1:** Annual Evaluation Report 2023



# EVALUATION ADVISORY COMMITTEE CHAIR REPORT

BOARD MEETING  
**James Hargreaves**  
6-7 June 2024, Geneva, Switzerland

[gavi.org](https://gavi.org)

Annex A



# Overarching issues and guidance

- Development of the 6.0 Centralised Evaluation Workplan
- Evaluation Function Review in 2024
- Partnership with other Global Health Institutions on suppliers
- Cross-cutting guidance related to all centralised evaluations



# Gavi 5.1 Centralised Evaluation Workplan

Evaluation		Supplier	Budget	Year				
			US\$	2021	2022	2023	2024	2025
Centralised evaluations of high strategic value to the Board to be commissioned in Gavi 5.1								
Evaluation of Gavi's initial response to COVID-19		EHG	US\$ 594,000	◇	◇			
COVAX Facility and COVAX AMC formative and baseline study (COVAX Phase 1)		ITAD	US\$ 1,080,000		◇			
Mid Term Evaluation of Gavi's 2021-2025 Strategy		EHG	US\$ 921,000		◇	◇	◇	
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities		IPSOS	US\$ 1,558,108		◇	◇	◇	
Evaluation of the operationalisation of Gavi's Strategy through Gavi's policies, programmatic guidance, and use of funding levers		EHG	US\$ 569,000	◇		◇		
COVAX Facility AMC and COVAX Pillar Delivery Efforts (COVAX Phase 2, Joint)		RTI (TBC)					◇	◇
Gavi's contribution to sustainability of coverage post-transition		TBD						◇
	Evaluation commissioning period							
	Evaluation implementation and delivery period							
◇	Deliverable that needs to be seen by the Evaluation Advisory Committee							

# Progress update – Sustainability/Post-Transition

Evaluation	Guidance	Progress Update
Gavi’s contribution to sustainability of coverage post-transition	<ul style="list-style-type: none"><li>Supported the Secretariat proposal postponing evaluative work on sustainability/post-transition until 2025, and to revisit the topic at the September 2024 EAC meeting;</li><li>Noted that the use case for this evaluation is dependent on the Board decision on the continuation of the Middle-Income Countries (MICs) Approach in Gavi 6.0;</li><li>Requested an update and additional information about the MICs approach learning agenda to inform the focus and value add of evaluative work on sustainability/MICs;</li><li>Raised the importance as well of differentiating between former-Gavi-eligible countries and the never-Gavi-eligible countries.</li></ul>	<ul style="list-style-type: none"><li>Postponed until 2025;</li><li>To be discussed again at the September 2024 meeting.</li></ul>

# Progress update – Zero-Dose Evaluation

Evaluation	Guidance	Progress Update
<b>Evaluation of Gavi's contribution to reaching zero-dose children and missed communities</b>	<ul style="list-style-type: none"> <li>Supported the plans for Phase 2, including the engagement of EAC Focal Points;</li> <li>Advised that evaluators should use all available relevant decentralised evaluation reports/information from Learning Hubs and reflect this in their reports;</li> <li>Emphasised the importance of in-depth country case study data and exploration of data sources for availability of data for contribution analysis, including communication with the partners like UNICEF, World Bank and WHO, resulting in an analysis plan.</li> </ul>	<p><u>Phase 1:</u></p> <ul style="list-style-type: none"> <li>Final report received in March 2024.</li> <li>Evaluation Management Response to be completed May 2024.</li> </ul> <p><u>Phase 2:</u></p> <ul style="list-style-type: none"> <li>Data collection April-June 2024</li> <li>Emerging findings: 21 June 2024</li> <li>Draft policy briefs + draft CA: w/c 23 August 2024</li> <li>Final policy briefs: 16 September 2024</li> <li>Overview report + proposals for phase 3: w/c 24 November 2024</li> </ul>



# Progress update – Mid-Term Evaluation

Evaluation	Guidance	Progress Update
<b>Mid-Term Evaluation of Gavi’s 2021-2025 Strategy</b>	<ul style="list-style-type: none"> <li>• The EAC requested feedback at the next EAC meeting on the perceived usefulness of the Mid-Term Evaluation, including both in relation to what new insights were generated that inform course correction and the Gavi 6.0 strategy;</li> <li>• Recognising the importance of clear concepts for evaluations, the MTE EAC Focal Points will prepare definitions / notes on relevant topics such as what is expected in terms of “country voice,” to inform future RFP development.</li> </ul>	<ul style="list-style-type: none"> <li>• Final report received in April 2024.</li> <li>• Evaluation Management Response to be completed early June 2024.</li> </ul>

# Progress update – COVAX Evaluation (Phase 2)

Annex A

Evaluation	Guidance	Progress Update
<b>COVAX Evaluation (Phase 2) (Joint Evaluation)</b>	<ul style="list-style-type: none"><li>• Advised that a plan be developed to extract maximum learning from the process of undertaking the joint evaluation;</li><li>• Emphasised the importance for the evaluation to examine partnership and how we work better as an alliance; with a particular focus on coordination and implementation at country level;</li><li>• Advised the development of a strategy for providing findings back to case study countries.</li></ul>	<ul style="list-style-type: none"><li>• Supplier contracted in March 2024.</li><li>• Inception report received 26 April 2024</li><li>• Emerging insights: July 2024</li><li>• Draft report: October 2024</li><li>• Final report: December 2024</li></ul>

# Thank you

# **EAC GUIDANCE**

EVALUATION ADVISORY COMMITTEE MEETING

20-21 March 2024, Geneva, Switzerland

# Item 3 – Gavi 5.1 Evaluation Workplan update

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Supported the Secretariat proposal postponing evaluative work on sustainability/post-transition until 2025, and to revisit the topic at the September 2024 EAC meeting;
- Noted that the use case for this evaluation is dependent on the Board decision on the continuation of the Middle-Income Countries (MICs) Approach in Gavi 6.0;
- Requested an update and additional information about the MICs approach learning agenda to inform the focus and value add of evaluative work on sustainability/MICs;
- Raised the importance as well of differentiating between former-Gavi-eligible countries and the never-Gavi-eligible countries; and
- Supported the ongoing work on Suppliers in partnership with other Global Health Institutions.



# Item 4 – Update on the Zero-Dose Evaluation

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Supported the plans for Phase 2, including the engagement of EAC Focal Points;
- Advised that evaluators should use all available relevant decentralised evaluation reports/information from Learning Hubs and reflect this in their reports; and
- Emphasised the importance of in-depth country case study data and exploration of data sources for availability of data for contribution analysis, including communication with the partners like UNICEF, World Bank and WHO, resulting in an analysis plan.

# Item 5 – Update on the Mid-Term Evaluation

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- The EAC requested feedback at the next EAC meeting on the perceived usefulness of the Mid-Term Evaluation, including both in relation to what new insights were generated that inform course correction and the Gavi 6.0 strategy; and
- Recognising the importance of clear concepts for evaluations, the MTE EAC Focal Points will prepare definitions / notes on relevant topics such as what is expected in terms of “country voice”, to inform future RFP development.

# Item 6 – Update On the COVAX Evaluation

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Advised that a plan be developed to extract maximum learning from the process of undertaking the joint evaluation;
- Emphasised the importance for the evaluation to examine partnership and how we work better as an alliance; with a particular focus on coordination and implementation at country level; and
- Advised the development of a strategy for providing findings back to case study countries.

# Item 7 – Evaluation Policy Operationalisation 1: Centralised evaluation work planning for Gavi 6.0

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- **Stakeholder consultation:** Encourage the Secretariat to consult with stakeholders and consult with relevant partners and map against other evidence generation functions such as learning labs, audit, decentralised evaluations;
- **Principles (workplanning):** Clarify purpose of the proposed principles for work planning; revisit content ahead of September 2024 meeting to align with Policy aims of credibility, utility and independence. Include issues of country representation/evidence partnerships; and
- **Issues for discussion:** Clarify distinction between these and Principles (including purpose); separate into approaches, methods and data issues; clarify focus of some, e.g. climate change; discuss with Focal Points prior to September meeting; consider spectrum of evaluation types.

# Item 8 – Evaluation Policy Operationalisation 2: MOPAN and Evaluation Function Review

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Advised that arrangements should be put in place to ensure independence and oversight of the review, including bringing in key stakeholders across Gavi's Board, Programme and Policy Committee (PPC) and Senior Leadership Team, and to keep them informed early and throughout the process;
- Noted that this review should consider the implications of all relevant development trends, e.g. *Leave No One Behind*, localisation, subnational focus, Lusaka agenda, and partnership; and
- Advised that a survey be added to the methodology for the review.



# Cross-evaluation recommendations

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance related to all centralised evaluations:

- Encouraged the continuation of follow-up meetings with EAC Focal Points and evaluators to clarify important issues, including EAC recommendations;
- Emphasised the importance of an integrated framework for methodologies when indicating that a suite of tools / techniques are going to be used; and
- Noted the importance of clear and documented decision criteria for country selection.

# EAC Engagement in Gavi 5.1 Evaluations (Mar 2024)

Annex B

EVALUATION	Steer. Co.	EAC Secondees	EAC Focal Points		
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities	Yes	David Hotchkiss Ezzeddine Mohsni	Adolfo Martinez Valle	Juan Pablo Gutierrez	Malabika Sarker*
Mid Term Evaluation of Gavi's 2021 – 2025 Strategy	No	n/a	James Hargreaves*	Rhoda Wanyenze	Juan Pablo Gutierrez
COVAX Evaluation: COVAX Facility and COVAX AMC (Gavi Secretariat) and COVAX Partner Delivery Efforts (Joint)	Yes	Adolfo Martinez Valle Julia Betts	David Hotchkiss	Ezzeddine Mohsni*	Penny Hawkins
Evaluation of Gavi's contribution to sustainability of coverage post-transition	TBD	n/a	Ezzeddine Mohsni	Malabika Sarker	Helen Evans*

# Additional EAC engagement (Mar 2024)

Workstream	EAC Focal Points		
Evaluation Function Review	Penny Hawkins*	Adolfo Martinez Valle	Helen Evans
Supplier Review	Penny Hawkins	Phyllis Dako-Gyeke	Adolfo Martinez Valle*
Procedures and processes	Juan Pablo Gutierrez	Malabika Sarker	Julia Betts*
Workplan – Gavi 6.0	Julia Betts	Rhoda Wanyenze	n/a

# Thank you

# REVIEW OF DECISIONS

EVALUATION ADVISORY COMMITTEE MEETING

20-21 March 2024, Geneva, Switzerland



# Decision 1: Gavi 5.1 Evaluation Workplan Update <sup>Annex C</sup>

The Gavi Alliance Evaluation Advisory Committee:

- **Approved** the revised multi-year (2021-2025) centralised evaluation workplan attached as Annex A to Doc 03.

# Thank you